Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Cash from Financing Activities (2023 - 2025)

Contineum Therapeutics has reported Cash from Financing Activities over the past 3 years, most recently at $93.5 million for Q4 2025.

  • Quarterly results put Cash from Financing Activities at $93.5 million for Q4 2025, up 14458.41% from a year ago — trailing twelve months through Dec 2025 was $112.7 million (up 3.38% YoY), and the annual figure for FY2025 was $112.7 million, up 3.38%.
  • Cash from Financing Activities for Q4 2025 was $93.5 million at Contineum Therapeutics, up from $19.1 million in the prior quarter.
  • Over the last five years, Cash from Financing Activities for CTNM hit a ceiling of $108.4 million in Q2 2024 and a floor of -$617000.0 in Q1 2023.
  • Median Cash from Financing Activities over the past 3 years was $366500.0 (2024), compared with a mean of $23.2 million.
  • Peak annual rise in Cash from Financing Activities hit 146861.54% in 2025, while the deepest fall reached 99.92% in 2025.
  • Contineum Therapeutics' Cash from Financing Activities stood at -$321000.0 in 2023, then soared by 300.0% to $642000.0 in 2024, then soared by 14458.41% to $93.5 million in 2025.
  • The last three reported values for Cash from Financing Activities were $93.5 million (Q4 2025), $19.1 million (Q3 2025), and $91000.0 (Q2 2025) per Business Quant data.